Obsidian Therapeutics, Inc. OBX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -24.40%
- 1 year
- -24.40%
- Market cap
- 817.26M
- EPS (ttm)
- -1.63
- Shares out
- 61.77M
- Forward P/E
- -7.98
- YTD return
- -24.40%
- 1-year return
- -24.40%
- Volume
- 626.85K
- Avg volume
- 395.13K
- Open
- 14.23
- Previous close
- 14.43
- Day's range
- 13.01 – 14.97
- 52-week range
- 11.52 – 49.97
- Beta
- 2.60
- Analysts
- Strong Buy
- Price target
- 39.00 (+194.8%)
- Earnings date
- Mar 31, 2025
2Y -4.26 (-24.34%)
Key statistics
- Enterprise value
- 1.37B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 34.45M
- Total debt
- 2.91M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 19.99
- 200-day average
- 19.99
Analyst view
Consensus: strong buy
- Target (low)
- 32.00
- Target (mean)
- 39.00
- Target (high)
- 43.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 31, 2025
Expected Mar 31, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 28, 2026 | Jun 30, 2026 | -1.63 | -1.38 | +0.25 | +15.34% |
| Mar 31, 2025 | Mar 31, 2025 | -60.00 | — | — | — |
| Dec 13, 2024 | Dec 31, 2024 | -58.00 | — | — | — |
| Aug 14, 2024 | Sep 30, 2024 | 165.45 | -14.00 | -179.45 | -108.46% |
| May 13, 2024 | Mar 31, 2024 | -58.89 | -16.00 | +42.89 | +72.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | Leerink Partners | init | — | Outperform |
| Sep 9, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | LifeSci Capital | init | — | Outperform |
| Aug 5, 2026 | Piper Sandler | init | — | Overweight |
About Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- obsidiantx.com
News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting 
Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel 
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting 
Obsidian Therapeutics (NASDAQ:OBX) Short Interest Update 
Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32 
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error 
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday 
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on OBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| EMERALD BIOVENTURES LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| FRIEDMAN MICHAEL R | Director | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| SORENSEN J. MEL | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |
| SORENSEN MELINDA | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |